Neurology News

The FDA has issued a complete response letter to AstraZeneca for its supplemental biologics license application of Ultomiris to treat adults with neuromyelitis optica spectrum disorder who are anti-aquaporin-4 antibody positive.

Within 12 months after childbirth, women who underwent infertility treatment had an increased risk for stroke-related hospitalization, according to a large population-based, retrospective cohort study published in JAMA Network Open.

Patients with post-incident dementia were more likely to begin central nervous system medications and less likely to discontinue cardiometabolic and anticholinergic medications, reflecting missed deprescribing opportunities, according to researchers.

A global clinical-stage biopharmaceutical company announced positive biomarker data from its exploratory phase 1 electroencephalogram biomarker study of novel and selective Kv7.2/Kv7.3 activator BHV-700 to treat epilepsy.

Compared with absolute values, serum neurofilament light chain Z scores were linked to higher effect size metrics and more accurate estimation of persistent neuroaxonal damage in pediatric populations, per data from The Lancet Neurology.

An implanted 10 kHz spinal cord stimulator plus conventional management was associated with pain relief and quality of life improvements at 2 years for adults with painful diabetic neuropathy, according to study findings.

Stoke Therapeutics Inc. has announced new positive data regarding its proprietary antisense oligonucleotide therapeutic to treat Dravet syndrome.

The B-glucocerebrosidase protein was a novel risk factor for Parkinson’s disease in African or African admixed populations and may assist in targeted treatments for these populations, according to a study published in The Lancet Neurology.

A clinical-stage biopharmaceutical company has announced the submission of an investigational new drug application to the FDA based upon results of a phase 2a clinical study of a novel lithium delivery system, AL001, for bipolar disorder.

The first patient has been dosed in a clinical trial with electron accelerator-produced Cu-67, according to a Wisconsin-based company specializing in radiopharmaceuticals for therapeutic and medical imaging applications announced.